A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.
Condition(s):Type 2 Diabetes MellitusLast Updated:May 31, 2019Completed
Hide Studies Not Open or Pending
Condition(s):Type 2 Diabetes MellitusLast Updated:May 31, 2019Completed
Condition(s):Parkinson’s DiseaseLast Updated:November 17, 2016Completed
Condition(s):Impaired Glucose Tolerance (IGT); DiabetesLast Updated:November 24, 2017Completed
Condition(s):HyperlipidemiaLast Updated:June 22, 2012Completed
Condition(s):Cocaine Use DisorderLast Updated:June 27, 2022Completed
Condition(s):Parkinson’s DiseaseLast Updated:September 16, 2022Completed
Condition(s):Diabetes Complications; Fatty LiverLast Updated:June 20, 2017Terminated
Condition(s):ObesityLast Updated:December 26, 2016Unknown status
Condition(s):InsulinomaLast Updated:October 14, 2022Active, not recruiting
Condition(s):Pancreatic CancerLast Updated:March 15, 2024Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.